Symbol List Views
Stock Details
CHARTS
COMPANY NEWS
STOCK ANALYSIS
FUNDAMENTALS
HOLDINGS
Edit Symbol List
Symbol Lookup
ARIA: Stock Quote & Summary Data
1.37%
| Last Sale | |
| Change Net / % |
|
| Best Bid / Ask | |
| 1y Target Est: | $ 4.00 |
| Today's High / Low | / |
| Share Volume | |
| 50 Day Avg. Daily Volume | 2,428,852 |
| Previous Close | $ 2.19 |
| 52 Wk High / Low | $ 3.48 / $ 0.72 |
| Shares Outstanding | 108,808,000 |
| Market Value | $ 235,025,280 |
| P/E Ratio | NE |
| Forward P/E (1yr) | NE |
| Earnings Per Share | $ -0.95 |
| Annualized Dividend | N/A |
| Ex Dividend Date | N/A |
| Dividend Payment Date | N/A |
| Current Yield | N/A |
| Beta | 1.99 |
| NASDAQ Official Open Price: | $ 2.17 |
| Date of NASDAQ Official Open Price: | Nov. 20, 2009 |
| NASDAQ Official Close Price: | $ 2.16 |
| Date of NASDAQ Official Close Price: | Nov. 20, 2009 |
Intraday Chart |
| 5d | 1m | 6m | 12m | More Charting |
Have a Question About ARIA?
Ask your question about about ARIAD Pharmaceuticals, Inc. (ARIA) by typing it in the box below. You'll get direct responses from other members of the NASDAQ Answers community!
Hot Topics in NASDAQ Answers
The most popular questions & answers in the
NASDAQ Answers Community:
Company Description (as filed with the SEC)
The following Business Section contains forward-looking statements, which involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain factors (see Part I, Item 1A: Risk Factors). Unless the content requires otherwise, references to “ARIAD,” “we,” “our,” and “us,” in this Annual Report on Form 10-K refer to ARIAD Pharmaceuticals, Inc. and our subsidiaries. Overview Our Business and Strategy We are engaged in the discovery and development of breakthrough medicines to treat cancers by regulating cell signaling with small molecules. We are developing a comprehensive approach to patients with cancer that addresses the greatest medical need — aggressive and advanced-stage cancers for which current treatments are inadequate. ... More ...
Links to all ARIAD Pharmaceuticals, Inc. (ARIA) Pages
Stock Analysis
Fundamentals
Holdings/Ownership
Company News for ARIA |
||
|
Bristol Licenses Arthritis Drug: BioBuzz - TheStreet 11/10/2009 9:20AM |
||
|
ARIAD to Present at the Lazard Capital Markets 6th Annual Healthcare Conference - Business Wire 11/10/2009 7:35AM |
||
|
Celgene in ASH Abstract Spotlight: BioBuzz - TheStreet 11/10/2009 6:31AM |
||
|
Doc Offers Top Hep C Drug Picks: BioBuzz - TheStreet 11/09/2009 1:54PM |
||
|
Xoma Waffles on Timing of Drug Partnership: BioBuzz - TheStreet 11/09/2009 10:23AM |
||
|
Sunrise, Kohlberg: Early Volume Plays - TheStreet 11/09/2009 8:48AM |
||
|
Ariad Upgraded, Xenoport Drug Delayed: BioBuzz - TheStreet 11/09/2009 7:51AM |
Consensus Recommendation |
|
Analyst Info |
|
| Annual EPS Est: | $ -0.83 |
| Quarterly EPS Est: | $ -0.16 |
| PEG Ratio: | N/A |
| Mean Recommendation: View Summary/View All |
1.70 |
